AI in Oncology Market: Growth, Size, Share, and Trends

Report Code HIT 9231
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma), & Region - Global Forecast to 2030

Overview

The global AI in oncology market is projected to reach USD 11.52 billion by 2030, from USD 2.45 billion in 2024, at a CAGR of 29.4%. This growth can be primarily attributed to rising investments in pharmaceutical and biotech companies to develop potential and advance cancer drugs to reduce the global cancer burden. AI streamlines drug discovery and development processes by offering predictive modeling, simulation, and advanced data analytics, making it easier to evaluate a drug’s safety and efficacy. This reduces drug discovery time and costs as it helps the user minimize the experimental work and optimize the clinical trial design.

AI in Oncology Market

Attractive Opportunities in the AI in Oncology Market

Asia Pacific

The Asia Pacific market is experiencing significant growth due to growing healthcare digitization, increasing awareness about early cancer detection, and the rising adoption of AI-driven diagnostic tools. Supportive government policies and a surge in R&D activities also contribute to market growth.

Advancements in data quality, machine learning algorithms, genomics, medical imaging, computing power, and clinical integration enhance AI models for cancer treatment and will significantly drive the market.

Emerging applications of AI in oncology, such as personalized treatment plans, drug development, and surgical planning and assistance, are expected to provide lucrative opportunities for market players.

The Asia Pacific AI in oncology market is projected to reach USD 2.74 billion by 2030, with a CAGR of 30.7%.

The limited availability of datasets remains a significant challenge in the AI in oncology market, mainly due to data privacy and protection regulations, limiting market growth opportunities.

Global AI in Oncology Market Dynamics

DRIVER: Growing prevalence of cancer

High incidences of cancer worldwide create urgency in finding effective and personalized diagnostic and treatment options. According to the International Agency for Research on Cancer (IARC), a cancer research agency of the World Health Organization (WHO), there were 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022. Lung cancer is the most common type of cancer, accounting for 12.4% of all diagnoses. Female breast cancer follows closely in second place, representing 11.6% of the total. Colorectal cancer ranks third, making up 9.6% of diagnoses. Prostate cancer accounts for 7.3%, while stomach cancer comprises 4.9% of all new cancer cases. IARC also projects that the number of new cancer cases will rise to 35 million by 2050, constituting a 77% increase. The rising cancer burden pushes for innovations to improve early detection, streamline care, and provide more targeted patient therapies. Al’s capacity to process large datasets, enhance early detection, tailor treatments, and optimize healthcare workflows is becoming increasingly critical. It can help tackle the challenges of cancer care by improving diagnostic precision, treatment effectiveness, and operational efficiency.

RESTRAINT: High initial costs

High initial investments are a major hindrance to the adoption of AI in the oncology market due to development, data acquisition, and regulatory approval charges. Companies operating in the oncology field incur many regulatory and data expenditures in addition to the enormous capital required for creating AI models. According to the Food and Drug Administration (FDA), regulatory processes can be costly. For instance, the cost of the 510(k) pre-market notification process is approximately USD 24,335, while the pre-market approval (PMA) process for class III devices costs up to USD 540,783. Regulatory costs for the De Novo Classification Request, which is necessary for new devices with no analog, amount to USD 162,235. These regulatory charges can be significant for small and medium AI solution providers, which already require substantial funding for research data collection and clinical trials. Data acquisition to train AI models is expensive and time-consuming, exceeding USD 1 million annually for a single dataset. Furthermore, companies must navigate differing national regulatory standards, which adds to the complexity and cost of their operations. The high upfront costs create a barrier to entry, making it difficult for smaller or early-stage companies to compete in the market.

 

OPPORTUNITY: Focus on personalized treatment plans

Cancer is a complex disease. AI is transforming oncology by allowing more personalized approaches to treatment. Analyzing individual patient characteristics, such as genetic profiles, tumor mutations, and clinical information, helps clinicians find tailored therapies that optimize treatment outcomes. This approach, particularly for treatments such as immunotherapy, aims to reduce side effects and improve patient responses. Compared to the traditional one-size-fits-all model, AI tools can predict how patients will respond to specific treatments. Many firms are increasingly adopting AI-related cancer care. For instance, in October 2024, Ataraxis AI (US) launched its availability for Ataraxis Breast, a prognostic and predictive tool for breast cancer that is 30% more accurate than standards at the moment. Similarly, GE Healthcare (US), in May 2024 at ESTRO 2024 Congress, announced its newest AI-based oncology solutions, such as Revolution RT Radiation Therapy CT Solution and the newly launched Intelligent Radiation Therapy (IRT) platform, which helps customers push boundaries for imaging precision, workflow efficiency, and individualized care. Earlier in June 2024, researchers at the University of Oxford developed an AI-based adaptive therapy approach for prostate cancer using deep reinforcement learning, which could potentially double relapse-free time.

CHALLENGES: Limited availability of datasets

The limited availability of datasets remains a significant challenge in the AI in oncology market, mainly due to data privacy and protection regulations. For instance, in the US, the Health Insurance Portability and Accountability Act (HIPAA) focuses on ensuring that health information remains confidential, secure, and accessible only to authorized individuals. Similarly, the General Data Protection Regulation (GDPR) provides broader protections for all personal data of EU residents, including health-related information. These regulations necessitate careful management of data privacy, and non-compliance can result in significant penalties of up to USD 21 million (EUR 20 million) or 4% of global revenue under GDPR and up to USD 2 million for severe violations of HIPAA. Other compliance challenges arise from the need to assess private requirements against increasing demands for high-quality datasets to train advanced AI models. This leads to fragmentation of data sources, inconsistent data formats, and labor-intensive data labeling, which impede the development of AI systems that can support precision oncology. To significantly advance AI applications in oncology treatment, it is crucial to address the limitations of these data.

Global AI in Oncology Market Ecosystem Analysis

The AI in oncology market ecosystem includes software providers, pharmaceutical and biotechnology companies, medical device/equipment companies, academic and research institutions, and government and regulatory agencies. The interaction among these players shapes the development, adoption, and advancement of AI-based technologies. Solution providers such as niche/point solution providers, integrated suite/platform providers, technology providers, and business process service providers in the market develop and cater AI-based software and services, such as diagnostic tools for imaging, predictive analytics for treatment planning, workflow automation to enhance efficiency and patient outcomes, and virtual assistants to provide reminders, or manage follow-ups.

AI in Oncology Market
 

The diagnosis and early detection segment accounted for the largest share of the AI in oncology market by application in 2023.

The early detection of cancer can significantly reduce mortality rates, as identifying cancer at an earlier stage improves survival and lowers treatment costs. In resource-poor settings, cancer is frequently diagnosed at an advanced stage, leading to lower survival rates and higher treatment costs. Early detection of cancer through AI-powered techniques, including radiomics and predictive analytics, allows for personalized treatment plans and better prognostic assessments, reducing mortality rates and improving overall survival. Improving access to diagnosis and ensuring timely treatment is crucial for minimizing delays in diagnosis. Currently, traditional machine learning techniques are more prevalent and support vector machines, as well as deep models such as Convolutional Neural Networks (CNN), which are increasingly deployed for earlier diagnoses in imaging diagnostics and molecular diagnostics. For instance, digital breast tomosynthesis combines AI to reduce recall rates and enhance detection. Similarly, low-dose CT scans, along with deep learning models, such as CNNs and Sybil, are useful for the prediction of lung cancer. Molecular tests such as lipid analysis for lung cancer and DeepGlioma for gliomas are also being combined with AI to refine early detection methods.

The solid tumor segment held the largest share of the AI in oncology market by cancer type in 2023.

In 2023, the solid tumor segment held the largest share of the AI in oncology market. Of all types of solid tumors, breast cancer ranked first due to its increasing prevalence worldwide. According to WHO, in 2022, breast cancer was the most common cancer among women in 157 countries. The statistics indicate there were 2.3 million diagnoses of breast cancer, along with 670,000 deaths. Similarly, the website breastcance.org reports that nearly 66% of breast cancer cases are locally diagnosed. The use of AI in early detection and diagnosis can help provide better survival rates and reduce treatment costs while improving the outcomes for patients. AI algorithms, such as deep learning and computer-aided detection (CAD), enhance the accuracy and speed of identifying tumors, improving early detection and treatment planning. Additionally, AI’s ability to analyze large datasets, including genomic and imaging information, supports personalized treatment approaches, driving its widespread adoption in breast cancer care. The integration of radiomics and machine learning models further refines tumor characterization and predicts treatment responses.

North America secured the largest share of the AI in oncology market in 2023.

In 2023, North America accounted for the largest share of the AI in oncology market. The region’s dominance can be primarily attributed to the significant presence of companies providing AI in oncology solutions, particularly in the US. Major US-based companies include GE Healthcare, ConcertAI, Oracle, NVIDIA Corporation, Predictive Oncology, PathAI, and CureMatrix. The North American AI in oncology market is further driven by ongoing advancements in machine learning and deep learning, rising accessibility of healthcare data, and increasing demand for precision medicine. Collaborations between tech firms and healthcare providers, along with established reimbursement policies, also enhance the integration of AI for cancer diagnostics, treatment planning, and precision medicine. For instance, in April 2024, Moffitt Cancer Center partnered with NVIDIA, Oracle, and Deloitte to reimagine cancer care using advanced AI and machine learning. In March 2024, NVIDIA collaborated with GE HealthCare to advance AI innovations with healthcare-specific foundation models powered by NVIDIA. Additionally, the region is home to several growing start-ups, such as CureMatch, Inc., Azra AI, and Triomics, that are driving innovation through AI-based oncology. These factors collectively position North America as a leading market in the field.

HIGHEST CAGR MARKET IN 2023
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION
AI in Oncology Market

Recent Developments of AI in Oncology Market

  • In October 2024, GE HealthCare (US) launched its new cloud-first application, CareIntellect for Oncology. This application combines multi-modal patient data from various systems into a unified view, leveraging generative AI to summarize clinical notes and reports.
  • In September 2024, F. Hoffmann-La Roche Ltd. (Switzerland) collaborated with Qritive (Singapore) to enhance cancer diagnostics and treatment and the adoption of AI among pathologists. This collaboration will enable Qritive’s AI-powered solutions to be fully integrated with Roche’s Navify Digital Pathology platform, which will help pathologists diagnose cancer more accurately and efficiently.
  • In September 2024, Oracle (US) partnered with Imagene AI Ltd. (US) to introduce CanvOI, an advanced pan-cancer foundation model aimed at supporting innovative research and development in digital pathology and oncology.
  • In June 2024, ConcertAI (US) collaborated with NVIDIA Corporation (US) to enhance translational and clinical development solutions within its CARA AI platform. ConcertAI will leverage NVIDIA’s AI expertise and infrastructure, including the Meta Llama 3 NIM, to enhance oncology research and treatment through advanced LLM workloads.
  • In June 2024, Predictive Oncology (US) launched a unique 3D cell culture model to advance cancer drug discovery, offering more accurate in vivo testing and better predictions for clinical outcomes and drug candidate selection.
  • In May 2024, ConcertAI (US) launched CARA AI, a platform that integrates multi-modal data management, predictive AI, and generative AI to streamline and enhance healthcare processes. The platform supports life sciences and healthcare professionals in exploring multi-modal real-world data (RWD) while utilizing AI-driven workflows.

Key Market Players

KEY PLAYERS IN THE AI IN ONCOLOGY MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in AI in Oncology Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2023
Forecast period 2024-2030
Forecast units Million/Billion (USD)
Segments covered Player Type, Application, Cancer Type, Technology, Deployment Model, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East Africa.

 

Key Questions Addressed by the Report

What are the major market players covered in the report?
Key players in the AI in oncology market are Siemens Healthineers (Germany), GE Healthcare (US), ConcertAI (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Oracle(US), NVIDIA Corporation(US), Koninklijke Philips N.V. (Netherlands), PathAI, Inc. (US) CureMetrix, Inc. (US), Mindpeak GmbH (Germany), Paige AI, Inc. (US), Predictive Oncology (US), and Exscientia (UK), among others.
Define AI in oncology market.
AI in oncology refers to using AI tools such as machine learning, natural language processing, and computer vision to analyze genomic data and large gene mutations unique to an individual’s cancer profile. These AI tools are adopted by various end users, including labs, research centers, hospitals, and biotechnology & pharmaceutical companies, to address the global cancer burden and the need for precision medicine in oncology.
Which region is expected to have the largest share of the AI in oncology market?
North America is expected to hold the largest share of the AI in oncology market during the forecast period.
Which end-user segments have been included in the AI in Oncology market report?
The report contains the following end-user segments:
  • Healthcare Providers
    • Hospitals & Clinics
    • Specialty Centers
    • Laboratories & Diagnostic Centers
    • Others
  • Pharmaceutical & Biotechnology Companies
  • Medical Device /Equipment Companies
  • Academic & Research Institutions
  • Government & Regulatory Agencies
  • Healthcare Payers
  • Others
How big is the global AI in Oncology market today?
The global AI in oncology market is estimated at USD 2.45 billion in 2024. It is projected to reach USD 11.52 billion by 2030, with a CAGR of 29.4%.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the AI in Oncology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
15
EXECUTIVE SUMMARY
35
PREMIUM INSIGHTS
68
MARKET OVERVIEW
89
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.3 INDUSTRY TRENDS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - MACHINE LEARNING
    - COMPUTER VISION
    - NATURAL LANGUAGE PROCESSING (NLP)
    COMPLEMENTARY TECHNOLOGIES
    - HIGH-PERFORMANCE COMPUTING
    - NEXT GENERATION SEQUENCING
    - DIGITAL TWINS
    - REAL-WORLD EVIDENCE/REAL-WORLD DATA
    ADJACENT TECHNOLOGIES
    - CLOUD COMPUTING
    - THERANOSTICS
    - AUGMENTED & VIRTUAL REALITY
  • 5.6 PORTER'S FIVE FORCE ANALYSIS
  • 5.7 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY ANALYSIS
    - NORTH AMERICA
    - EUROPE
    - ASIA PACIFIC
    - REST OF THE WORLD
  • 5.8 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR THE AI IN ONCOLOGY MARKET
    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 PRICING ANALYSIS
    INDICATIVE PRICING OF AI IN ONCOLOGY SOFTWARE, BY DEPLOYMENT MODEL (2023) (QUALITATIVE)
    AVERAGE SELLING PRICE OF AI IN ONCOLOGY PLATFORMS, BY REGION (2023)
  • 5.10 KEY CONFERENCES & EVENTS 2024-2025
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN THE BUYING PROCESS
    BUYING CRITERIA
  • 5.12 UNMET NEEDS/END USER EXPECTATIONS IN AI IN ONCOLOGY MARKET
  • 5.13 ECOSYSTEM MAPPING
  • 5.14 CASE STUDY ANALYSIS
  • 5.15 TRENDS/DISRUPTION IMPACTING CUSTOMER’S BUSINESS
  • 5.16 AI IN ONCOLOGY MARKET, INVESTMENT AND FUNDING SCENARIO
  • 5.17 IMPACT OF AI/GEN AI IN ONCOLOGY MARKET
AI IN ONCOLOGY MARKET, BY PLAYER TYPE
113
  • 6.1 INTRODUCTION
  • 6.2 NICHE/POINT SOLUTION PROVIDERS (INCLUDING PLATFORM & SERVICE)
  • 6.3 INTEGRATED SUITE/PLATFORM PROVIDERS (INCLUDING PLATFORM & SERVICE)
  • 6.4 TECHNOLOGY PROVIDERS (ONLY SOFTWARE)
  • 6.5 BUSINESS PROCESS SERVICE PROVIDERS
AI IN ONCOLOGY MARKET, BY APPLICATION
156
  • 7.1 INTRODUCTION
  • 7.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & VALIDATION
    LEAD IDENTIFICATION & OPTIMIZATION
    DE NOVO DRUG DESIGN
  • 7.3 DRUG DEVELOPMENT
    PRECLINICAL TESTING
    PREDICTIVE MODELING FOR HUMAN TRIALS
    CLINICAL TRIAL OPTIMIZATION
    ADAPTIVE TRIAL DESIGN & MONITORING
  • 7.4 DIAGNOSIS & EARLY DETECTION
    IMAGING & RADIOLOGY
    - MAMMOGRAPHY
    - COMPUTED TOMOGRAPHY
    - MAGNETIC RESONANCE IMAGING (MRI)
    - NUCLEAR IMAGING (PET & SPECT)
    - X-RAY IMAGING
    - ULTRASOUND
    - OTHERS (IF ANY)
    DIGITAL PATHOLOGY & HISTOPATHOLOGY
    LIQUID BIOPSY & BIOMARKER DETECTION
    GENETIC RISK PREDICTION
  • 7.5 TREATMENT PLANNING & PERSONALIZATON
    PERSONALIZED TREATMENT PLANNING
    - PRECISION MEDICINE & GENOMIC ANALYSIS
    - RADIOMICS AND RADIOGENOMICS
    - PREDICTIVE MODELS FOR TREATMENT RESPONSE
    - TREATMENT RECOMMENDATION SYSTEMS
    RADIATION THERAPY
    CHEMOTHERAPY
    IMMUNOTHERAPY
    TARGETED THERAPY
    - COMBINATION & DOSE OPTIMIZATION
    - AI-GUIDED DRUG DELIVERY
    SURGICAL PLANNING & ASSISTANCE
    - PREOPERATIVE IMAGING AND 3D MODELING
    - INTRAOPERATIVE GUIDANCE AND ROBOTICS
    - POSTOPERATIVE ANALYSIS & RECOVERY
  • 7.6 PATIENT ENGAGEMENT & REMOTE MONITORING
    SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE
    REMOTE PATIENT MONITORING
    PATIENT EDUCATION & EMPOWERMENT
  • 7.7 POST TREATMENT SURVEILLANCE & SURVIVORSHIP CARE
    RECURRENCE MONITORING
    LONG-TERM OUTCOME PREDICTION
    MENTAL HEALTH & SUPPORT SYSTEMS
  • 7.8 DATA MANAGEMENT & ANALYTICS
  • 7.9 OTHER APPLICATIONS (ONCOLOGY WORKFLOW MANAGEMENT, RESOURCE ALLOCATION, AND ADMINISTRATIVE SUPPORT AMONG OTHERS)
AI IN ONCOLOGY MARKET, BY CANCER TYPE
189
  • 8.1 INTRODUCTION
  • 8.2 SOLID TUMORS
    BREAST CANCER
    LUNG CANCER
    PROSTATE CANCER
    COLORECTAL CANCER
    BRAIN TUMORS
    OTHER TUMORS (LIVER, KIDNEY, PANCREAS, SKIN, ETC.)
  • 8.3 HEMATOLOGIC MALIGNANCIES
    LEUKEMIA
    LYMPHOMA
    MULTIPLE MYELOMA
    OTHER HEMATOLOGIC MALIGNANCIES
  • 8.4 OTHERS (IF ANY)
AI IN ONCOLOGY MARKET, BY TECHNOLOGY
199
  • 9.1 INTRODUCTION
  • 9.2 MACHINE LEARNING
    DEEP LEARNING
    - CONVOLUTIONAL NEURAL NETWORKS (CNN)
    - RECURRENT NEURAL NETWORKS (RNN)
    - GENERATIVE ADVERSARIAL NETWORKS (GAN)
    - GRAPH NEURAL NETWORKS (GNN)
    - OTHERS
    SUPERVISED LEARNING
    REINFORCEMENT LEARNING
    UNSUPERVISED LEARNING
    OTHER MACHINE LEARNING TECHNOLOGIES (IF ANY)
  • 9.3 NATURAL LANGUAGE PROCESSING (NLP)
  • 9.4 CONTEXT-AWARE PROCESSING AND COMPUTING
  • 9.5 COMPUTER VISION
  • 9.6 IMAGE ANALYSIS (INCLUDING OPTICAL CHARACTER RECOGNITION)
  • 9.7 OTHERS (IF ANY)
AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL
210
  • 10.1 INTRODUCTION
  • 10.2 ON-PREMISES MODEL
  • 10.3 CLOUD-BASED MODEL
  • 10.4 HYBRID MODEL
AI IN ONCOLOGY MARKET, BY END-USER
316
  • 11.1 INTRODUCTION
  • 11.2 HEALTHCARE PROVIDERS
    HOSPITALS & CLINICS
    SPECIALTY CENTERS
    LABORATORIES & DIAGNOSTIC CENTERS
    OTHERS
  • 11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.4 MEDICAL DEVICE/EQUIPMENT COMPANIES
  • 11.5 ACADEMIC & RESEARCH INSTITUTIONS
  • 11.6 GOVERNMENT & REGULATORY AGENCIES
  • 11.7 HEALTHCARE PAYERS
  • 11.8 OTHERS (IF ANY)
AI IN ONCOLOGY MARKET, BY REGION
346
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    US
    CANADA
    NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 12.3 EUROPE
    GERMANY
    FRANCE
    UK
    SPAIN
    ITALY
    REST OF EUROPE
    EUROPE: MACROECONOMIC OUTLOOK
  • 12.4 ASIA PACIFIC
    CHINA
    JAPAN
    INDIA
    REST OF ASIA PACIFIC
    ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 12.5 LATIN AMERICA
    BRAZIL
    MEXICO
    REST OF LATIN AMERICA
    LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 12.6 MIDDLE EAST AND AFRICA
    GCC COUNTRIES
    REST OF MIDDLE EAST & AFRICA
    MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
COMPETITIVE LANDSCAPE
378
  • 13.1 OVERVIEW
  • 13.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 13.4 MARKET SHARE ANALYSIS
  • 13.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 13.6 VALUATION AND FINANCIAL METRICS OF KEY AI IN ONCOLOGY VENDORS
  • 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2023
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - APPLICATION FOOTPRINT
    - DEPLOYMENT FOOTPRINT
    - END USER FOOTPRINT
  • 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - DETAILED LIST OF STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 13.9 COMPETITIVE SCENARIO AND TRENDS
    PRODUCT LAUNCHES
    DEALS
    OTHERS
COMPANY PROFILES
388
  • 14.1 KEY PLAYERS
    SIEMENS HEALTHINEERS AG
    GE HEALTHCARE
    CONCERTAI
    MEDTRONIC
    F. HOFFMANN-LA ROCHE LTD
    ORACLE
    NVIDIA CORPORATION
    KONINKLIJKE PHILIPS N.V.
    PREDICTIVE ONCOLOGY
    EXSCIENTIA
    PATHAI, INC.
    CUREMETRIX INC.
    MINDPEAK GMBH
    PAIGE AI, INC.
    INSILICO MEDICINE
  • 14.2 TEMPUS
    IKTOS
TEMPUS
396
  • 15.1 OTHER PLAYERS
    AZRA AI
    CUREMATCH, INC.
    ONCOLENS
    TRIOMICS
    CLINAKOS.
    PERTHERA, INC.
    CELLWORKS GROUP, INC.
    BIOMY, INC.
APPENDIX
398
  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 16.3 AVAILABLE CUSTOMIZATIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS

The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Breakdown of Primary Participants:

AI in Oncology Market

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
AI in Oncology Market

Data Triangulation

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

  • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
  • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
  • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

Stakeholders

  • Clinical/Physician Centers
  • AI Providers
  • Clinical Research Organizations
  • Pharmaceutical/Biopharmaceutical Companies
  • Research and Development (R&D) Companies
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers/Universities/Hospitals
  • Government Agencies
  • Regulatory Agencies
  • Clinical Researchers
  • Clinical Research Organizations
  • Accountable Care Organizations
  • Investors and Venture Capitalists

Report Objectives

  • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
  • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
  • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
  • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
  • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
  • To profile the key players and comprehensively analyze their market sizes and core competencies
  • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in AI in Oncology Market

DMCA.com Protection Status